BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies
A Alu, H Lei, X Han, Y Wei, X Wei - Journal of Hematology & Oncology, 2022 - Springer
Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …
Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances
T Wen, J Wang, Y Shi, H Qian, P Liu - Leukemia, 2021 - nature.com
Bruton's tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential
efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new …
efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new …
Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects
HY Estupiñán, A Berglöf, R Zain… - Frontiers in cell and …, 2021 - frontiersin.org
The cytoplasmic protein-tyrosine kinase BTK plays an essential role for differentiation and
survival of B-lineage cells and, hence, represents a suitable drug target. The number of BTK …
survival of B-lineage cells and, hence, represents a suitable drug target. The number of BTK …
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised …
Background Both single-agent ibrutinib and chlorambucil plus obinutuzumab have shown
superior efficacy to chlorambucil monotherapy and are standard first-line treatments in …
superior efficacy to chlorambucil monotherapy and are standard first-line treatments in …
[HTML][HTML] Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Clinical trials that led to ibrutinib's approval for the treatment of chronic lymphocytic leukemia
showed that its side effects differ from those of traditional chemotherapy. Reasons for …
showed that its side effects differ from those of traditional chemotherapy. Reasons for …
Chronic lymphocytic leukaemia
Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in
the past two decades have led to the development of new prognostic tools and novel …
the past two decades have led to the development of new prognostic tools and novel …
NCCN guidelines® insights: Chronic Lymphocytic leukemia/small Lymphocytic lymphoma, version 3.2022: Featured updates to the NCCN Guidelines
The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton's tyrosine …
(CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton's tyrosine …
Advances in covalent kinase inhibitors
Over the past decade, covalent kinase inhibitors (CKI) have seen a resurgence in drug
discovery. Covalency affords a unique set of advantages as well as challenges relative to …
discovery. Covalency affords a unique set of advantages as well as challenges relative to …
Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial
S Stilgenbauer, B Eichhorst, J Schetelig… - Journal of Clinical …, 2018 - ascopubs.org
Purpose Venetoclax is an orally bioavailable B-cell lymphoma 2 inhibitor. US Food and
Drug Administration and European Medicines Agency approval for patients with 17p deleted …
Drug Administration and European Medicines Agency approval for patients with 17p deleted …
Chronic lymphocytic leukaemia: from genetics to treatment
Chronic lymphocytic leukaemia (CLL), the most frequent type of leukaemia in adults, is a
lymphoproliferative disorder that is characterized by the expansion of monoclonal, mature …
lymphoproliferative disorder that is characterized by the expansion of monoclonal, mature …